Personalis: Best-in-Class NGS Partner for Individualised Neoantigen-based Therapy Design and Response Monitoring
Time: 4:40 pm
day: Day One
Details:
- ImmunoID NeXT; multidimensional view of the tumour and the TME from a single sample, including comprehensive neoantigen identification (with accelerated TATs)
- NeXT Personal; ultra-sensitive, tumour-informed liquid biopsy assay for MRD detection and therapy response monitoring, with simultaneous variant tracking
